ONCAlert | 2017 NANETS Symposium

Latest NewsMORE >>

Updated results from the TRANSCEND study demonstrated that liso-cel (lisocabtagene maraleucel), formally known as JCAR017, induced an 81% objective response rate and a 63% complete remission rate in patients with relapsed/refractory diffuse large B-cell lymphoma.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.